FDA approves first drug to decrease urine protein in IgA nephropathy, a rare kidney disease

[FDA]

FDA has granted accelerated approval for Tarpeyo (budesonide) delayed release capsules to reduce proteinuria (increased protein levels in the urine) in adults with primary immunoglobulin A (IgA) nephropathy at risk of rapid disease progression.


Baca selengkapnya di : http://www.fda.gov...